FDA warns Little Moon Essentials over CGMP failures and unapproved topical analgesic drugs made in Dania Beach, Florida.
What happened
FDA inspected the drug manufacturing facility from January 16 to 18, 2024. Investigators found the company did not test incoming components, did not perform finished-product release testing, did not validate manufacturing processes, lacked stability data to support five-year expiration dates, and had inadequate quality-unit procedures. FDA also found five topical analgesic products were unapproved new drugs and misbranded based on their labeling claims.
What FDA found
The company failed to test each incoming component for identity and failed to validate supplier test results, relying instead on certificates of analysis.
21 CFR 211.84(d)(1) and 211.84(d)(2)The company failed to perform appropriate laboratory release testing for each batch of drug product before distribution.
21 CFR 211.165(a)The company failed to establish written production and process control procedures and failed to validate its manufacturing processes.
21 CFR 211.100(a)The company failed to support expiration dates with stability testing and failed to establish a written stability program.
21 CFR 211.166(a) and 211.137(a)The company failed to establish adequate written quality control unit responsibilities and procedures and failed to follow them.
21 CFR 211.22(d)Five topical analgesic products were unapproved new drugs and misbranded because their labels claimed external analgesic uses without FDA-approved applications.
FD&C Act sections 505(a), 301(d), and 502(ee)
What FDA wants
FDA tells the company to fix CGMP failures, provide independent assessments and CAPA plans, and test reserve samples for DEG/EG and stability; DEG/EG results are due within 30 calendar days and stability reserve testing within 60 days.
Who should pay attention
- brands that buy OTC topical drugs or hand sanitizer from contract manufacturers
- retailers and distributors selling Little Moon topical analgesics
- companies relying on supplier certificates of analysis for glycerin or ethanol
This is a summary. Read the original letter on fda.gov.